Canadian Securities ExchangeThe Daily Bell

Bright Minds Biosciences Inc.

CSE:DRUG View the CSE listing

From the CSE on LinkedIn

Phase II trials for an epilepsy drug and peer success are fuelling a standout year for Bright Minds Biosciences…Jan 21, 2026Phase II trials for an epilepsy drug and peer success are fuelling a standout year for Bright Minds Biosciences (CSE:DRUG). In The Global Issue of Canadian Securities Exchange Magazine, we sat down with Chief Executive Officer Ian McDonald to discuss the company's focus on its serotonin-targeting drug, how its lead compound, BMB-101, avoids negative side effects, and its plans to take the molecule to the edge of commercialization. Read now: https://lnkd.in/gqTBdaDN #AlwaysInvestedRead on LinkedIn

1 video on CSE TV

2 stories on the blog

  • Epilepsy Drug in Phase II Trials and Peer Success Combine to Fuel a Standout YearFor three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer’s disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy. But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are…

    Jan 21, 2026CSE Issuer StoriesBright Minds Biosciences Inc. (CSE:DRUG)

  • Canadian Securities Exchange Magazine: The Global Issue – Now Live!Welcome to the latest issue of Canadian Securities Exchange Magazine, your source for in-depth stories of entrepreneurs from a wealth of different industries. The global capital markets map is being redrawn in real time. Economies are facing an inflection point: never before has the world been more interconnected through technology and trade; however, geopolitical tensions…

    Dec 18, 2025MagazineBright Minds Biosciences Inc. (CSE:DRUG)